# Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus

> **NCT00597506** · PHASE2 · COMPLETED · sponsor: **Herbert Hurwitz** · enrollment: 50 (actual)

## Conditions studied

- Colorectal Adenocarcinoma

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT00597506
- **Lead sponsor:** Herbert Hurwitz
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2012-12-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00597506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00597506, "Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT00597506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*